Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Marchetti

Showing results (71-80 of 450) with videos related to

Pageof 45
Sort By:
Current Oncology (Toronto, Ont.)|June 2, 2021
A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast CancerMarta Piras, Martina Panebianco, Matteo Garibaldi, et al.
Tumori|May 9, 2015
Widespread renal polycystosis induced by crizotinibMarco Di Girolamo, Ida Paris, Francesco Carbonetti, et al.
Breast (Edinburgh, Scotland)|December 25, 2016
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspectivePaolo Marchetti, Nicolai Maass, Joseph Gligorov, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2013
Endocrine side effects induced by immune checkpoint inhibitorsSalvatore Maria Corsello, Agnese Barnabei, Paolo Marchetti, et al.
Clinical Colorectal Cancer|July 21, 2016
Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II TrialPaolo Marchetti, Annalisa Milano, Chiara D'Antonio, et al.
European Journal of Endocrinology|September 5, 2013
Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypothesesFrancesco Torino, Agnese Barnabei, Rosa Maria Paragliola, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 6, 2020
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabineAndrea Botticelli, Simone Scagnoli, Michela Roberto, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 10, 2018
Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological wardSebastiano Mercadante, Paolo Marchetti, Claudio Adile, et al.
Cancer Treatment Reviews|April 7, 2026
Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integrationVittorio Studiale, Ada Taravella, Matteo Landi, et al.
Journal of Pain and Symptom Management|July 10, 2003
Knowledge and attitudes of Italian medical oncology residents toward the approach and treatment of painGiampiero Porzio, Federica Aielli, Filomena Narducci, et al.
Pageof 45

Showing results (71-80 of 450) with videos related to

Sort By:
Pageof 45
Current Oncology (Toronto, Ont.)|June 2, 2021
A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast CancerMarta Piras, Martina Panebianco, Matteo Garibaldi, et al.
Tumori|May 9, 2015
Widespread renal polycystosis induced by crizotinibMarco Di Girolamo, Ida Paris, Francesco Carbonetti, et al.
Breast (Edinburgh, Scotland)|December 25, 2016
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspectivePaolo Marchetti, Nicolai Maass, Joseph Gligorov, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2013
Endocrine side effects induced by immune checkpoint inhibitorsSalvatore Maria Corsello, Agnese Barnabei, Paolo Marchetti, et al.
Clinical Colorectal Cancer|July 21, 2016
Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II TrialPaolo Marchetti, Annalisa Milano, Chiara D'Antonio, et al.
European Journal of Endocrinology|September 5, 2013
Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypothesesFrancesco Torino, Agnese Barnabei, Rosa Maria Paragliola, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 6, 2020
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabineAndrea Botticelli, Simone Scagnoli, Michela Roberto, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 10, 2018
Characteristics and care pathways of advanced cancer patients in a palliative-supportive care unit and an oncological wardSebastiano Mercadante, Paolo Marchetti, Claudio Adile, et al.
Cancer Treatment Reviews|April 7, 2026
Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integrationVittorio Studiale, Ada Taravella, Matteo Landi, et al.
Journal of Pain and Symptom Management|July 10, 2003
Knowledge and attitudes of Italian medical oncology residents toward the approach and treatment of painGiampiero Porzio, Federica Aielli, Filomena Narducci, et al.
Pageof 45